Literature DB >> 17356539

Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Ruijiang Song1, Shuqin Liu, Kam W Leong.   

Abstract

Transfection of DNA vaccines with chemokines may recruit dendritic cells (DCs) locally to capture the antigenic genes and their gene products to generate enhanced CD8(+) cytotoxic T lymphocytes (CTLs). In this study, we investigated the effects of macrophage inflammatory protein (MIP)-1 alpha, MIP-3 alpha, and MIP-3beta on human immunodeficiency virus (HIV) Gag DNA vaccination. The chemokine plasmids markedly enhanced the local infiltration of inflammatory cells and increased the presence of CD11c(+) B7.2(+)-activated DCs. MIP-1 alpha and MIP-3 alpha were potent adjuvants in augmenting CTLs and afforded strong protection to immunized animals against challenge with vaccinia virus expressing Gag (vv-Gag). However, decreased humoral response was observed. MIP-3beta plasmid did not dramatically alter immunity. The chemokine inoculation time with respect to DNA vaccine priming was also investigated. The injection of pMIP-3 alpha three days before Gag plasmid (pGag) vaccination markedly increased specific CTLs compared with simultaneous injection and led to higher protection against vv-Gag. Immunity was also shifted toward a T-helper type-1 (Th1) response. In contrast, inoculation with pMIP-3 alpha three days after pGag vaccination shifted immunity toward a Th2 response. Our data suggest that administration of a chemokine with DNA vaccines offers a valuable strategy to modulate the efficacy and polarization of specific immunity and that chemokine-antigen timing is critical in determining overall biological effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356539      PMCID: PMC2365720          DOI: 10.1038/mt.sj.6300129

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

Review 1.  The role of chemokines in the regulation of dendritic cell trafficking.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Leukoc Biol       Date:  1999-07       Impact factor: 4.962

2.  Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.

Authors:  Y Lu; K Q Xin; K Hamajima; T Tsuji; I Aoki; J Yang; S Sasaki; J Fukushima; T Yoshimura; S Toda; E Okada; K Okuda
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response.

Authors:  S Schrum; P Probst; B Fleischer; P F Zipfel
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

4.  Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC.

Authors:  M Baba; T Imai; M Nishimura; M Kakizaki; S Takagi; K Hieshima; H Nomiyama; O Yoshie
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

5.  Differential CC chemokine-induced enhancement of T helper cell cytokine production.

Authors:  W J Karpus; N W Lukacs; K J Kennedy; W S Smith; S D Hurst; T A Barrett
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

6.  The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.

Authors:  I M Belyakov; J D Ahlers; B Y Brandwein; P Earl; B L Kelsall; B Moss; W Strober; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

7.  Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Authors:  Katsuyoshi Furumoto; Luis Soares; Edgar G Engleman; Miriam Merad
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

8.  CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine.

Authors:  Andree Zibert; Stefan Balzer; Manfred Souquet; Trong Hung Quang; Cristina Paris-Scholz; Marie Roskrow; Dagmar Dilloo
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

9.  Requirement of MIP-1 alpha for an inflammatory response to viral infection.

Authors:  D N Cook; M A Beck; T M Coffman; S L Kirby; J F Sheridan; I B Pragnell; O Smithies
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

10.  CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.

Authors:  D R Greaves; W Wang; D J Dairaghi; M C Dieu; B Saint-Vis; K Franz-Bacon; D Rossi; C Caux; T McClanahan; S Gordon; A Zlotnik; T J Schall
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

View more
  21 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

3.  In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells.

Authors:  Ankur Singh; Shalu Suri; Krishnendu Roy
Journal:  Biomaterials       Date:  2009-06-27       Impact factor: 12.479

4.  CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Authors:  T Nguyen-Hoai; M Pham-Duc; M Gries; B Dörken; A Pezzutto; J Westermann
Journal:  Cancer Gene Ther       Date:  2016-04-08       Impact factor: 5.987

5.  Statistical modeling using early markers of innate immunity to explain variation in humoral responses to influenza vaccine in older adults.

Authors:  Richard B Kennedy; Pritish K Tosh; Krista M Goergen; Diane E Grill; Ann L Oberg; Gregory A Poland
Journal:  Vaccine       Date:  2015-06-16       Impact factor: 3.641

6.  Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.

Authors:  Xinmei Xie; Lin Wang; Wenliang Yang; Ruishuang Yu; Qingli Li; Xiaobin Pang
Journal:  Invest New Drugs       Date:  2015-05-09       Impact factor: 3.850

7.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

8.  Macrophage Inflammatory Protein-3 Alpha (MIP-3α)/CCL20 in HIV-1-Infected Individuals.

Authors:  Najib Aziz; Roger Detels; L Cindy Chang; Anthony W Butch
Journal:  J AIDS Clin Res       Date:  2016-06-14

9.  PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.

Authors:  Bingbing Dai; Liang Xiao; Paul D Bryson; Jinxu Fang; Pin Wang
Journal:  Mol Ther       Date:  2012-05-15       Impact factor: 11.454

10.  Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.

Authors:  Tae Gun Kang; Hyo Jin Park; Jihyun Moon; June Hyung Lee; Sang-Jun Ha
Journal:  Immune Netw       Date:  2021-06-17       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.